US and Europe Cell and Gene Therapy Manufacturing Services Market is expected to reach US$ 16,869.1 million by 2030

Publisher: The Insight Partners

Cell Therapy Segment to Lead US and Europe Cell and Gene Therapy Manufacturing Services Market During 2022–2030

According to our new research study on “US and Europe Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 –Country Analysis – by Type, Indication, Application, and End User,” the US and Europe cell and gene therapy manufacturing services market size is expected to grow from US$ 4,773.5 million in 2022 to US$ 16,869.1 million by 2030; it is estimated to register a CAGR of 17.1% during 2022–2030.

Key factors driving the US and Europe cell and gene therapy manufacturing services market growth include increase in number of approvals of cell and gene therapies and increasing popularity of outsourcing cell and gene therapy manufacturing.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00029984 Based on type, the US and Europe cell and gene therapy manufacturing services market is segmented into cell therapy and gene therapy. The cell therapy segment held a larger US and Europe cell and gene therapy manufacturing services market share in 2022 and is anticipated to register a higher CAGR of 17.3% in the US and Europe cell and gene therapy manufacturing services market during the forecast period. Cell therapy helps treat disorders and diseases by restoring or changing certain groups of cells or providing cells to carry therapy through the body. Cell therapy forms or modifies cells outside the body before introducing into the patient. The cells may derive from the patient (autologous cells) or a donor (allogeneic cells). The growth of the cell therapy segment is attributed to the increasing number of products entering the market, the potential application of cell therapies in the treatment of autoimmune diseases, cancer, and infectious diseases, and the high number of ongoing clinical trials. More than 360 clinical trials focusing on CAR-T cell therapies and other cell-based therapies are being studied to interpret the potential of these therapies for treating various disease indications. Therefore, the demand for advanced therapy manufacturing services is anticipated to increase in the coming years. Thus, the above-mentioned factors support the US and Europe cell and gene therapy manufacturing services market growth for cell therapy segment.

Cell therapy is subsegmented as autologous and allogenic. Autologous segment held a larger share of the market in 2022. However, the allogenic segment is anticipated to register a higher CAGR in the US and Europe cell and gene therapy manufacturing services market. The advantages of allogeneic treatments include a potentially wider availability, and diversity of cells and tissues. The growing awareness about allogeneic cell therapies, an upsurge in funds for new cell lines, and the development of advanced genomics methods for cell analysis benefit the allogeneic cell therapies segment. Physicians are inclined toward the therapeutic use of allogeneic therapies as these cell therapies have allowed enormous leaps in the treatment of various cancer types (leukemia or lymphoma) and other diseases.

Many regenerative therapeutic applications have gained approval for clinical trials in the US and Europe due to the effectiveness of allogeneic stem cell therapeutics. With such approvals and the subsequent launch of new product lines, the demand for stem therapy using allogeneic stem cell therapeutics has increased in recent years. For instance, Alofisel developed by TiGenix (Takeda) is the first allogeneic stem cell-based therapy that received marketing authorization in Europe for the treatment of complex perianal fistulas in Crohn’s disease. Thus, such factors support the US and Europe cell and gene therapy manufacturing services market growth in the coming years.

Thermo Fisher Scientific Inc, Merck KGaA, Charles River Laboratories International Inc, Lonza Group AG, WuXi AppTec Co Ltd, Catalent Inc, Takara Bio Inc, Nikon Corp, FUJIFILM Holdings Corp, National Resilience Inc, and Oxford BioMedica Plc are among the leading companies operating in the US and Europe cell and gene therapy manufacturing services market. 

Based on type, the US and Europe cell and gene therapy manufacturing services market is segmented into cell therapy and gene therapy. In terms of indication, the US and Europe cell and gene therapy manufacturing services market is segmented into cancer, orthopaedics, and others. By application, the US and Europe cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In terms of end user, the US and Europe cell and gene therapy manufacturing services market is segmented into pharmaceutical and biotechnology companies and contract research organization (CROs). By country, the US and Europe cell and gene therapy manufacturing services market is segmented into US and Europe (Germany, UK, France, Italy, Spain, and Rest of Europe).

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com